DelSiTech Ltd

DelSiTech Ltd is excited to be hosting a webinar focusing on long-acting injectables starting on the 12th of September, chaired by Dr. Frederic Dargelas, PhD, MBA. It is a real privilege to have Prof. René Holm of the University of Southern Denmark, Dr. Peter Markland of Tolmar Pharmaceuticals, and Dr. Jokinen Mika of DelSiTech provide their unique perspectives on the long-acting injectable technology space as it stands today. We believe that long-acting injectables are already and will increasingly be transformative forms of care for patients around the globe. In support of bringing these technologies and treatments to patients, we are pleased to note that the webinar can be attended free of charge. To attend, go ahead and fill out the registration form through the link below: https://lnkd.in/e8dqSNu7 Many thanks to Arena International Webinars for helping us organize this opportunity.

DelSiTech Ltd is excited to announce the appointment of Mr. Carl-Åke Carlsson to its Board of Directors! Read more from the full press release below.

💉 DelSiTech Ltd is thrilled to announce an exclusive licensing agreement with a leading global pharmaceutical company!   This exclusive agreement grants them rights to our groundbreaking #SilicaMatrix controlled release technology for the development and commercialization of an undisclosed long-acting injectable drug product. Under the terms of the agreement, #DelSiTech will receive an upfront payment of $9M and potential milestone payments exceeding $200M, plus royalties on net sales.   This is the second global license agreement to be announced by DelSiTech in 2024 and we look forward to sharing more updates in the future. Read the full press release linked in the comments below!   #DelSiTech #DrugDelivery #LicensingAgreement 

DelSiTech Ltd is thrilled to announce a global license and development agreement with Tolmar, marking a significant milestone in our partnership since their investment in January 2024.   Under the terms of the agreement, #Tolmar will obtain a global license to utilize #DelSiTech’s proprietary Silica Matrix technology for two undisclosed drug targets. In addition, both companies will collaborate to expand the development of additional drug products across a range of therapeutic areas.   This #collaboration further strengthens our partnership with Tolmar and holds immense promise for innovative #DrugDelivery solutions. We look forward to sharing more updates in the future.   Read more about the collaboration here: https://bit.ly/4bE2ayg #DelSiTech #drugdevelopment #SilicaMatrix 

We are pleased to announce the successful completion of a EUR 10 million financing round, the largest single financing round in the Company’s history.   The financing was co-led by new investors DRW Venture Capital LLC and Tolmar International Ltd, with participation from existing DelSiTech Ltd shareholders.   Funds will be used to advance #DelSiTech’s proprietary silica-based drug delivery technology platform and expand its in-house manufacturing capability to support the development programs of multiple partners.   We look forward to sharing further updates as we continue to address high unmet #clinical and #commercial needs for the benefit of patients.   Read more about the financing, here: http://bit.ly/47DjFLS   #DelSiTech #drugdelivery #financing

As winter arrives, we find ourselves reflecting on this autumns successful events. Thank you to all of our partners for their support and dedication to development of long-acting therapies this year at Bio Europe. #bioeurope2023

DelSiTech Ltd was excited to join the World Vaccine Congress Europe 2023 in mid-October in the magnificent city of Barcelona! Our CEO, Dr. Lasse Leino gave a presentation on how DelSiTech Silica Matrix Technology can be used to develop slow and sustained release vaccine formulations and how this could improve the efficacy of vaccines.   DelSiTech is currently working together with multiple industry and non-profit partners in the slow/sustained release vaccine a field. Hopefully, in the upcoming vaccine conferences DelSiTech is able to share first in vivo results on novel Silica Matrix based vaccines. #wvc2023 #wvceu #vaccines